# Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

> **NCT07371910** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- HRD-Positive/HER2-Negative Advanced Breast Cancer

## Interventions

- **DRUG:** Chemotherapy/ADC Regimen
- **DRUG:** Fluorizoparib
- **DRUG:** Apatinib
- **DRUG:** Physician's Choice Chemotherapy/ADC Regimen

## Key facts

- **NCT ID:** NCT07371910
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2031-03
- **Final completion:** 2031-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371910, "Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07371910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*